These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 20233092)
1. A fluorescence anisotropy assay for the muscarinic M1 G-protein-coupled receptor. Huwiler KG; De Rosier T; Hanson B; Vogel KW Assay Drug Dev Technol; 2010 Jun; 8(3):356-66. PubMed ID: 20233092 [TBL] [Abstract][Full Text] [Related]
2. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands. Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140 [TBL] [Abstract][Full Text] [Related]
3. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. Tahtaoui C; Parrot I; Klotz P; Guillier F; Galzi JL; Hibert M; Ilien B J Med Chem; 2004 Aug; 47(17):4300-15. PubMed ID: 15294002 [TBL] [Abstract][Full Text] [Related]
4. Development of a homogeneous high-throughput live-cell G-protein-coupled receptor binding assay. Lee PH; Miller SC; van Staden C; Cromwell EF J Biomol Screen; 2008 Sep; 13(8):748-54. PubMed ID: 18460694 [TBL] [Abstract][Full Text] [Related]
5. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes. Burke RE Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217 [TBL] [Abstract][Full Text] [Related]
6. On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. Tahtaoui C; Guillier F; Klotz P; Galzi JL; Hibert M; Ilien B J Med Chem; 2005 Dec; 48(24):7847-59. PubMed ID: 16302823 [TBL] [Abstract][Full Text] [Related]
7. [35S]GTPgammaS binding in G protein-coupled receptor assays. Cooper T; McMurchie EJ; Leifert WR Methods Mol Biol; 2009; 552():143-51. PubMed ID: 19513647 [TBL] [Abstract][Full Text] [Related]
8. Action of the muscarinic toxin MT7 on agonist-bound muscarinic M1 receptors. Olianas MC; Adem A; Karlsson E; Onali P Eur J Pharmacol; 2004 Mar; 487(1-3):65-72. PubMed ID: 15033377 [TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry. Whitehurst CE; Nazef N; Annis DA; Hou Y; Murphy DM; Spacciapoli P; Yao Z; Ziebell MR; Cheng CC; Shipps GW; Felsch JS; Lau D; Nash HM J Biomol Screen; 2006 Mar; 11(2):194-207. PubMed ID: 16490772 [TBL] [Abstract][Full Text] [Related]
10. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Lazareno S; Birdsall NJ Mol Pharmacol; 1995 Aug; 48(2):362-78. PubMed ID: 7651370 [TBL] [Abstract][Full Text] [Related]
11. Selectivity profile of muscarinic toxin 3 in functional assays of cloned and native receptors. Olianas MC; Ingianni A; Maullu C; Adem A; Karlsson E; Onali P J Pharmacol Exp Ther; 1999 Jan; 288(1):164-70. PubMed ID: 9862767 [TBL] [Abstract][Full Text] [Related]
12. Ratiometric Ca+2 measurement in human recombinant muscarinic receptor subtypes using the Flexstation scanning fluorometer. Gupta S; Singh RK; Nanda K; Chatterjee M; Tiwari A; Sundaram S; Gupta D; Chugh A; Dastidar S; Ray A J Recept Signal Transduct Res; 2009; 29(2):100-6. PubMed ID: 19288301 [TBL] [Abstract][Full Text] [Related]
13. Site of action of the general anesthetic propofol in muscarinic M1 receptor-mediated signal transduction. Murasaki O; Kaibara M; Nagase Y; Mitarai S; Doi Y; Sumikawa K; Taniyama K J Pharmacol Exp Ther; 2003 Dec; 307(3):995-1000. PubMed ID: 14534362 [TBL] [Abstract][Full Text] [Related]
14. The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms. Lewandowicz AM; Vepsäläinen J; Laitinen JT Br J Pharmacol; 2006 Feb; 147(4):422-9. PubMed ID: 16402041 [TBL] [Abstract][Full Text] [Related]
15. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Krejcí A; Tucek S Mol Pharmacol; 2001 Oct; 60(4):761-7. PubMed ID: 11562438 [TBL] [Abstract][Full Text] [Related]
16. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821 [TBL] [Abstract][Full Text] [Related]
17. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of acetylcholine muscarinic M(1) receptor function by the M(1)-selective ligand muscarinic toxin 7 (MT-7). Olianas MC; Maullu C; Adem A; Mulugeta E; Karlsson E; Onali P Br J Pharmacol; 2000 Oct; 131(3):447-52. PubMed ID: 11015294 [TBL] [Abstract][Full Text] [Related]
19. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions. Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151 [TBL] [Abstract][Full Text] [Related]
20. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors. Lanzafame A; Christopoulos A J Pharmacol Exp Ther; 2004 Mar; 308(3):830-7. PubMed ID: 14617684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]